PopulationsHumans

Eligibility for GLP-1 Receptor Agonists for Obesity across 91 Countries

ADA Scientific Sessions 2025 Abstract

The paper

Sang Gune K. Yoo, Michaela Theilmann, Megan W. Lam,

Dessie V. Tien, Maja Marcus, Nomathemba C. Chandiwana, Justine Ina Davies, Mohammed Kumail Ali, David Flood,

Jennifer Manne‐Goehler

St. Louis

ADA Scientific Sessions 2025 Abstract · 13 Jun 2025

Presented at ADA Scientific Sessions 2025 · Poster 1362-P

doi.org/10.2337/db25-1362-p

GLP-1 drugs added to SGLT2 inhibitors linked to lower kidney risk
Diabetes, Obesity & Metabolism · 4 Oct 2026
Orforglipron matches insulin glargine on cardiovascular safety
Lancet · 4 Oct 2026
A triple-target drug cut body weight by up to 19.7% in a trial
Cell Metabolism · 8 Oct 2026
Retatrutide reduces weight and pain in adults with obesity
The New England Journal of Medicine · 4 Oct 2026